CJC-1295: Research Applications

🔬 Adult Growth Hormone Deficiency (GHD) and Somatopause

CJC-1295 has been investigated as an alternative to daily rhGH injections for adults with GHD or age-related somatopause. Phase I data (Teichman et al., 2006) in healthy adults (n=64) demonstrated that a single SC injection produced dose-dependent GH increases (1.5 to 3-fold above baseline) lasting 9–11 days, with IGF-1 increases of 1.3 to 1.9-fold sustained for 9–11 days. [3] This durability profile positions CJC-1295 with DAC as a potential once-weekly or biweekly pituitary secretagogue in GHD research models.

🔬 Body Composition Research

GH and IGF-1 regulate body composition by stimulating lipolysis (fat breakdown) and protein synthesis (muscle anabolism). Preclinical studies in rodent models demonstrate that sustained GHRH receptor activation increases lean body mass and reduces adipose tissue — effects mediated via IGF-1 signaling in muscle and fat tissue. [5] CJC-1295 with DAC produces continuous IGF-1 elevation that may amplify these body composition effects compared to pulsatile delivery approaches.

🔬 Metabolic Research — HIV-Associated Lipodystrophy

Phase II trials in adults with HIV-associated lipodystrophy (fat redistribution syndrome) were initiated by ConjuChem before the company's closure. This population was selected because HIV antiretroviral therapy causes peripheral fat loss and central fat accumulation, with secondary GH axis suppression. CJC-1295 with DAC was hypothesized to restore GH/IGF-1 physiology and normalize fat distribution — a clinically meaningful endpoint in this population. [4] Development was discontinued without publication of Phase II results.

🔬 Pediatric GHD (Preclinical Model)

Alba et al. (2006) studied GRF analogues in GH-deficient rat models, establishing the preclinical basis for dosing regimens translatable to pediatric GHD research. CJC-1295 with DAC showed dose-dependent normalization of growth parameters in hypophysectomized rodents — the standard in vivo model for GHD. [7]

🔬 Pituitary Biology and GH Axis Research

CJC-1295 with DAC serves as a pharmacological tool compound for studying tonic vs. pulsatile GH axis stimulation. Because it provides continuous, week-long GHRHr activation, it enables researchers to decouple the effects of GH pulse frequency from GH pulse amplitude — questions relevant to optimizing GH replacement therapy dosing regimens. [2]